Deep Vein Thrombosis; A Paradigm Change in Treatment through Drug-Free Clot Removal

Descrizione del progetto

Il trattamento di pericolosi coaguli di sangue potrebbe diventare ben presto più semplice e meno costoso

I calcoli renali sono dolorosi ma raramente letali. Il loro trattamento spazia dal bere semplicemente molta acqua fino all’intervento chirurgico in casi difficili. Per quanto riguarda i coaguli nelle vene profonde del corpo (trombosi venosa profonda), la questione è assai diversa. I coaguli di grandi dimensioni possono staccarsi e incastrarsi nelle arterie polmonari, bloccandole con esiti spesso letali. Durante i ricoveri ospedalieri prolungati vengono somministrati potenti trombolitici come forma di trattamento, ma al loro uso è correlato un significativo aumento del rischio di sanguinamento. VETEX sta introducendo sul mercato un nuovo trattamento rivoluzionario per consentire l’eliminazione di un coagulo, riducendo al minimo l’uso di farmaci trombolitici. La riuscita del trattamento ridurrà gli oneri per il sistema sanitario e migliorerà la vita di milioni di persone.

Obiettivo

Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.

Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.

DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.

Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.

Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.

Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high
growth strategy.

Campo scientifico

Programma(i)

Argomento(i)

EIC-SMEInst-2018-2020 - SME instrument

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

VETEX MEDICAL LIMITED

Contribution nette de l'UE

€ 2 485 644,00

Indirizzo

218 BUSINESS INNOVATION CENTRE, NUIG
H91 FC85 GALWAY
Irlanda

PMI

Sì

Regione

Ireland Northern and Western West

Tipo di attività

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Collegamenti

Contatta l’organizzazione

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Costo totale

€ 3 550 920,00